Obesity Featured Articles

  1. Here's How FDA's Accelerated Approval Pathway Has Evolved Since '24 5/5/2026

    FDA's accelerated approval guidance kicked off a rebalancing of new drug approval pathways. Since its 2024 release, the agency has been building on it in a few key areas.

  2. From Hint To Headline: FOMAT Acquires Site Network 5/5/2026

    FOMAT Medical CEO, Nick Focil, talks about the company’s acquisition of site network Topography Health — a deal that expands FOMAT’s national footprint and reflects a broader trend of site network growth aimed at scaling access, data, and operational reach.

  3. Start Fast, Scale Seamlessly: Why A Different Oncology Model Was Needed 5/1/2026

    Oncology programs don’t lose momentum because the science fails, but because execution fractures as complexity grows. Learn how continuity-first operating models help sponsors move faster.

  4. Keeping Oncology Programs Moving As Complexity Increases 5/1/2026

    As oncology trials grow more complex, speed depends on clarity. Consistent oversight and shared data help teams make confident decisions faster without losing control.

  5. Scaling Oncology Trials Without Losing Momentum 5/1/2026

    As oncology programs expand, complexity often replaces momentum. Explore how scaling introduces hidden operational challenges and why anticipating continuity early helps teams stay aligned.

  6. Why Early Phase Speed Depends On Oncology Expertise 5/1/2026

    Early phase oncology speed depends on confident, oncology‑specific decisions made upfront. Learn why scientific expertise, realistic planning, and foresight determine whether programs maintain momentum.

  7. The Industry Talks Access — Fabian Sandoval Builds It 5/1/2026

    Fabian Sandoval is redefining what a clinical research site looks like — building trust through community partnerships, media, and education to improve trial access and awareness long before enrollment begins.

  8. A Biomarker Playbook For Building Faster, Smarter Clinical Trials 5/1/2026

    Not every trial needs a biomarker, but every development leader should be assessing whether they can be effectively used to improve trial design, boost enrollment, reduce operational waste, and increase the likelihood that a study will answer the question it was built to answer.

  9. Coordinator Services For High-Volume Research Sites 4/30/2026

    Remove the administrative burden of travel and reimbursements from your site staff with a service providing takes over direct communication, travel inquiries, and administrative entries

  10. ALS Researchers Use Stratification, Diverse Endpoints To Address Heterogeneity 4/30/2026

    Coya Therapeutics' Fred Grossman dives into innovative trial design elements and a novel biomarker that might better account for clinical and functional progression in Coya's ALS trial studying a dual immunomodulatory therapy.